Profectus Enters Research Agreement With Malaria Vaccine Initiative

August 25, 2009
Profectus BioSciences, Inc., a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, announced Tuesday it has entered into a research collaboration agreement with the PATH Malaria Vaccine Initiative to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus vector technology as a preventative malaria vaccine.
Yahoo! Finance